ACAN and rheumatoid arthritis: Our study demonstrates that effective 15-month anti-inflammatory treatment with TNFαI was associated with improvement of aggrecan turnover, assessed through serum levels of aggrecan-derived synthesis and degradation molecules (CS846 and AGC, respectively) and ADAMTS levels in female RA patients.